<DOC>
	<DOCNO>NCT03073486</DOCNO>
	<brief_summary>The objective study assess safety efficacy Olumacostat Glasaretil Gel compare vehicle patient acne vulgaris</brief_summary>
	<brief_title>A Study Olumacostat Glasaretil Gel Subjects With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Signed informed consent , subject legal adult age , sign assent Age ≥ 9 year Clinical diagnosis facial acne vulgaris define : At least 20 inflammatory lesion , At least 20 noninflammatory lesion , Investigator Global Assessment 3 great Active cystic acne acne conglobata , acne fulminans , secondary acne Two active nodulocystic lesion face Clinically significant abnormal laboratory ECG result Subjects actively participate experimental therapy study receive experimental therapy within 30 day 5 halflives ( whichever longer ) Baseline visit Treatment overthecounter topical medication treatment acne vulgaris include benzoyl peroxide , topical antiinflammatory medication , corticosteroid , αhydroxy/glycolic acid face within 2 week prior Baseline Treatment systemic antibiotic systemic antiacne drug topical retinoid within 4 week prior Baseline Treatment new hormonal therapy dose change exist hormonal therapy within 12 week prior Baseline ( hormonal therapy include , limited , estrogenic progestational agent birth control pill ) . Use androgen receptor blocker ( spironolactone flutamide ) within 2 week prior Baseline . Oral retinoid use ( e.g. , isotretinoin ) within 12 month prior Baseline vitamin A supplement great 10,000 units/day within 6 month prior Baseline Facial procedure ( chemical laser peel , microdermabrasion , etc . ) within past 8 week</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>